Insider Selling: Adaptive Biotechnologies Co. (NASDAQ:ADPT) President Sells 39,070 Shares of Stock

Adaptive Biotechnologies Co. (NASDAQ:ADPTGet Free Report) President Julie Rubinstein sold 39,070 shares of the company’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $3.47, for a total transaction of $135,572.90. Following the completion of the sale, the president now owns 472,754 shares in the company, valued at approximately $1,640,456.38. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Adaptive Biotechnologies Stock Performance

Shares of ADPT stock opened at $3.45 on Friday. Adaptive Biotechnologies Co. has a 52-week low of $2.61 and a 52-week high of $9.08. The company has a 50-day simple moving average of $4.09 and a two-hundred day simple moving average of $4.71. The company has a market capitalization of $500.57 million, a price-to-earnings ratio of -2.21 and a beta of 1.27.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ADPT. JPMorgan Chase & Co. grew its position in shares of Adaptive Biotechnologies by 17.7% during the 1st quarter. JPMorgan Chase & Co. now owns 329,115 shares of the company’s stock valued at $4,569,000 after acquiring an additional 49,451 shares during the period. HighTower Advisors LLC bought a new position in shares of Adaptive Biotechnologies during the 1st quarter valued at approximately $160,000. Citigroup Inc. grew its position in shares of Adaptive Biotechnologies by 16.6% during the 1st quarter. Citigroup Inc. now owns 28,375 shares of the company’s stock valued at $394,000 after acquiring an additional 4,047 shares during the period. PNC Financial Services Group Inc. grew its position in shares of Adaptive Biotechnologies by 176.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 5,293 shares of the company’s stock valued at $73,000 after acquiring an additional 3,380 shares during the period. Finally, Bank of Montreal Can bought a new position in shares of Adaptive Biotechnologies during the 1st quarter valued at approximately $1,284,000. 94.31% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on ADPT shares. William Blair restated an “outperform” rating on shares of Adaptive Biotechnologies in a report on Friday, November 10th. The Goldman Sachs Group lowered their target price on shares of Adaptive Biotechnologies from $11.00 to $5.00 and set a “neutral” rating on the stock in a report on Friday, February 16th. JPMorgan Chase & Co. reduced their price objective on shares of Adaptive Biotechnologies from $11.00 to $8.00 and set an “overweight” rating for the company in a research report on Thursday, February 15th. Finally, Piper Sandler reduced their price objective on shares of Adaptive Biotechnologies from $13.00 to $6.00 and set an “overweight” rating for the company in a research report on Monday, November 13th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, Adaptive Biotechnologies currently has an average rating of “Moderate Buy” and an average target price of $7.25.

View Our Latest Stock Report on Adaptive Biotechnologies

Adaptive Biotechnologies Company Profile

(Get Free Report)

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals.

See Also

Insider Buying and Selling by Quarter for Adaptive Biotechnologies (NASDAQ:ADPT)

Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.